date,title,content,company
"  January 12, 2023 / 08:41 AM IST  ",Nykaa in focus as undisclosed shareholder offers 14.2 million shares in block deal: Report,"An undisclosed shareholder of FSN E-Commerce Ventures Limited, the parent company of Nykaa, is offering 14.2 million shares in a block trade, Bloomberg reported on January 12. The total amount of shares up for the block deal amount to 0.5 percent of the company's total equity.Reportedly, the shares are being offered at Rs 148.90 a piece - a discount of 4 percent to the company's current market price - as the shareholder is looking to raise $26 million via block. In the previous session, the shares of FSN E-Commerce Ventures settled 2.95 percent higher at Rs 155.10 apiece on the BSE, while the benchmark Sensex closed 9.98 points or 0.02 percent lower at 60,105.50.Moneycontrol could not independently verify the report.Also Read: How do Nykaa's profitability goals look in light of increasing competition?According to CNBC-TV18, Citigroup Global Markets India is the bookrunner to this transaction.In December, 3.7 crore shares or 1.3 percent equity of FSN E-Commerce Ventures changed hands in a block deal, it had reported.Earlier in November, in another block deal 1.8 crore shares of FSN E-Commerce Ventures changed hands. Lighthouse India was likely the seller.",FSN E-Commerce Ventures Ltd.
"  January 12, 2023 / 06:28 PM IST  ","HCL Tech logs 20% rise in Q3 net profit, beats estimates","HCL Technologies on January 12 reported a 20 percent rise in its consolidated net profit for the quarter ended December 2022 (Q3FY23) at Rs 4,096 crore as against Rs 3,442 crore a year back.Its consolidated revenue from operations increased 19.61 percent to Rs 26,700 crore against Rs 22,321 crore in the corresponding quarter last year, the company said in an exchange filing.The numbers beat estimates as according to a poll of brokerages, consolidated revenue was expected to come in Rs 26,026 crore, up 16.6 percent year-on-year (YoY) growth, while consolidated profit after tax (PAT) was estimated to increase 10.6 percent YoY to Rs 3,796 crore.Revenue in terms of constant currency was up 5 percent sequentially and 13.1 percent year-on-year (YoY).The company said it won 17 large deals during the quarter - seven in the services segment and 10 in software. The total contract value (TCV) of new deal wins was at $2.35 billion, up 10 percent YoY.The Board of Directors has also declared an interim dividend of Rs 10 per equity share for FY23. The record date is set as January 20. The Payment date shall be February 1, 2023.HCL Tech said the EBIT margin during the quarter was at 19.6 percent, up 165 bps sequentially. Net margin stood at 15.3 percent, up 117 bps sequentially.CC. Our margins at 19.6 percent this quarter, increased 60 basis points YoY.""Providing guidance for FY23, the company said revenue is expected to be between 13.5-14 percent YoY in constant currency. Services revenue is expected to be 16-16.5 percent YoY in constant currency. It said the EBIT margin will likely narrow to 18-18.5 percent.The last twelve-month attrition rate - a measure of employees leaving the company voluntarily - was at 21.7 percent down from 23.8 percent in the September quarter and higher than 19.8 percent in the December quarter last year.",HCL Technologies Ltd.
"  January 12, 2023 / 10:32 AM IST  ","HCL Technologies edges up ahead of Q3 earnings, analysts expect 10% profit growth","HCL Technologies shares edged higher in the morning session on January 12 ahead of its December quarter earnings due later in the day.At 10:13am, HCL Technologies was quoting at Rs 1,067.90, up Rs 13.10, or 1.24 percent, on the BSE. It has touched an intraday high of Rs 1,074.00 and an intraday low of Rs 1,061.Analysts are forecasting a 3 percent sequential growth in constant currency (CC) terms, which is likely to be greater than its peers.According to a poll of brokerages, consolidated revenue might come in at Rs 26,026 crore, registering 16.6 percent yearon-year (YoY) growth, while consolidated profit after tax (PAT) is expected to increase 10.6 percent YoY to Rs 3,796 crore.Catch all the market action on our live blogAt its investor day held on December 8 in New York, the company’s management had flagged off that Q3 FY23 will see higher-than-expected furloughs, with BFSI and hi-tech being the problem areas.Analysts are pegging earnings before interest and tax (EBIT) margin at 18.9 percent for the quarter. This indicates a near 95-basis-point (bps) expansion. One basis point is one-hundredth of a percentage point.The total contract value in terms of deal wins might be flat in Q3 FY23 at $2 billion, compared to $2.38 billion recorded in the previous quarter. As indicated earlier by the management, the company believes it will continue to win deals in North America while Europe may see some slowdown.Domestic research and broking firm has an 'accumulate' rating on the stock with target of Rs 1,192 per share.""HCL Tech is among the top four IT services companies based out of India and provides a vast gamut of services like ADM, Enterprise solutions, Infrastructure management services etc. IT services witnessed robust growth of over 5 percent QoQ constant currency (CC) in Q4FY22 which was offset by seasonal de-growth of 24 percent QoQ CC in the product business of,"" it said.""New deal total contract value (TCV) at $2.3 billion was up by 6 percent QoQ and included many large deals. Strong deal wins will help drive growth in the services business, which should make up for the continued softness in the product business.""At the current market price, the stock is trading at a significant discount to the other large cap IT companies like Infosys and TCS and offers tremendous value at current levels given market leader status in Infrastructure management.",HCL Technologies Ltd.
"  January 12, 2023 / 07:52 PM IST  ",Infosys raises full-year growth guidance | 10 key highlights,"Infosys, the country's second-largest IT services exporter, clocked better-than-expected top line and bottom line growth in the quarter ended December, although operating performance was slightly below analyst estimates.Here are 10 key highlights from its quarterly scorecard:1) Bottom lineThe IT services company reported a 9.4 percent sequential growth in consolidated profit at Rs 6,586 crore, above the CNBC-TV18 poll estimate of Rs 6,480 crore.Year-on-year growth in the bottom line was 13.4 percent. Earnings were partly led by higher other income, which grew by 33 percent QoQ and 50 percent YoY.2) Top lineConsolidated revenue was Rs 38,318 crore, increasing 4.9 percent sequentially and 20.2 percent YoY and beating analyst estimates.In dollar terms, revenue grew by 2.3 percent QoQ and 9.6 percent YoY to $4.66 billion, with constant currency top line growth at 2.4 percent and 13.7 percent, respectively.According to the average of estimates of analysts polled by CNBC-TV18, revenue was expected at Rs 37,918 crore and dollar revenue at $4.62 billion with constant currency growth of 1.2 percent on a sequential basis.Also read: Infosys Q3 Net profit surges 13% to Rs 6,586 crore, beats estimates; deal wins at $3.3 bnYear-on-year growth was in double digits for most business segments and geographical regions in constant currency terms.""Revenue growth was strong in the quarter, with both digital business and core services growing. This is a clear reflection of our deep client relevance, industry-leading digital, cloud, and automation capabilities, and the unrelenting dedication of our employees”, CEO Salil Parekh said.3) Digital Business and Deal WinsDigital business comprised 62.9 percent of overall revenue and grew 4 percent sequentially to Rs 2,930 crore. The year-on-year growth was 17.8 percent and in constant currency, it increased 21.7 percent.The total contract value of large deals was the strongest in eight quarters at $3.3 billion, against $2.7 billion in the previous quarter.""As reflected in the large deals momentum, we continue to gain market share as a trusted transformation and operational partner for our clients,"" Parekh said. ""Our end-to-end capabilities and global scale make us a preferred choice as clients look at consolidating vendors. We remain focused on helping businesses accelerate their digital agenda to uncover new value and growth, as well as improve operational and cost effectiveness.""4) Full-Year GuidanceInfosys revised its full-year (FY23) revenue growth guidance to 16-16.5 percent from 15-16 percent earlier, with strong deal wins.Its full-year EBIT margin guidance was unchanged at 21-22 percent.Click Here To Read All Earnings Related News5) Operating PerformanceOperating margins remained resilient due to cost optimisation benefits which offset the impact of seasonal weakness in operating parameters, chief financial officer Nilanjan Roy said.The IT services company, with more than Rs 6.2 lakh crore market capitalisation, reported consolidated EBIT (earnings before interest and tax) at Rs 8,242 crore, growing 4.7 percent sequentially and 10.1 percent on-year.EBIT margin at 21.5 percent for the quarter was unchanged compared to previous quarter but fell 2 percentage points from a year-ago period.The numbers came in below CNBC-TV18 poll estimates of Rs 8,298 crore and 21.8 percent, respectively.6) Business Segments PerformanceIn constant currency terms, Infosys reported 5.5 percent YoY growth in the financial services segment and 12.7 percent growth each in retail and communications.The company’s energy, utilities, resources & services division registered 25.9 percent on-year growth, while the manufacturing segment grew 36.8 percent.The hi-tech and life sciences businesses clocked 10.4 percent and 5 percent growth, respectively, compared to a year ago.7) Revenue by GeographyInfosys said business from North America grew 10.5 percent on-year in constant currency terms, and the Europe region clocked 25.3 percent growth.The contribution of the rest of the world was also strong, reporting 11.9 percent on-year growth, although the India business underperformed other geographies, registering a 5.4 percent decline on-year.Active clients at the end of December grew 4 percent to 1,850 from the previous quarter and 6.4 percent from a year ago.The company added 17 clients in the $1 million+ category, 13 clients in the $10 million+ band and two clients in the $50 million+ section. It lost one client in the $100 million+ category.8) HeadcountInfosys had 346,845 employees at the end of December compared with 345,218 at the end of September. The number of women employees as a percentage of the total was 39.4 percent against 39.3 percent in the previous quarter.9) Attrition RateRoy said the attrition rate reduced meaningfully during the quarter ended December and is expected to decline further in the near term.The attrition rate at 24.3 percent for the quarter dropped from 27.1 percent in the September quarter and 25.5 percent in the year-ago period.10) Capital AllocationInfosys started buying back shares through the open market route on December 7, 2022, and will continue till June 6, 2023.",Infosys Ltd.
"  January 12, 2023 / 04:53 PM IST  ","Infosys Q3: Net profit surges 13% to Rs 6,586 crore, beats estimates; deal wins at $3.3 bn","Infosys on January 12 reported a 13.4 percent rise in its consolidated net profit for the quarter ended December 2022 at Rs 6,586 crore. The country's second-largest IT firm had reported a net profit of Rs 5,809 crore in the same quarter last year.Its consolidated revenue from operations increased 20.2 percent to Rs 38,318 crore against Rs 31,867 crore in the corresponding quarter last year, Infosys said in an exchange filing.The reported numbers beat estimates. According to a poll of brokerages, consolidated revenue was expected to come in at Rs 37,613 crore, up 18 percent year-on-year (YoY) growth. In comparison, consolidated profit after tax (PAT) was estimated to increase 10.5 percent YoY to Rs 6,418 crore.In constant currency terms, YoY revenue growth was at 13.7 percent while sequential growth stood at 2.4 percent. Digital revenue comprised 62.9 percent of overall revenues and grew at 21.7 percent in constant currency.Year-on-year growth was in double digits for most business segments and geographical regions in constant currency terms. The IT firm added that the total contract value for the quarter was the strongest in the last eight quarters at $3.3 billion. The operating margin of the company, however, slipped to 21.5 percent from 23.5 percent a year ago. It was flat sequentially.reduced meaningfully during the quarter and is expected to decline further in the near term.""Last twelve month IT services voluntary attrition rate - measuring the percentage of employees leaving the company during the period- declined to 24.3 percent. It was 27.1 percent in the previous quarter and 25.5 percent in the same quarter last year.Infosys revised its FY23 guidance higher to 16-16.5 percent. It retained FY23 operating margin guidance at 21-22 percent.“Our revenue growth was strong in the quarter, with both digital business and core services growing,” said Salil Parekh, CEO and MD, Infosys. “As reflected in the large deal's momentum, we continue to gain market share as a trusted transformation and operational partner for our clients. Our end-to-end capabilities and global scale make us a preferred choice as clients look at consolidating vendors.”",Infosys Ltd.
"  January 12, 2023 / 07:32 AM IST  ","Trade Spotlight | What should you do with Oil India, HPCL, Max Financial Services on Thursday?","The market has seen consolidation within a range of 100 points on the Nifty50 and finally settled flat with a negative bias on January 11 as traders looked cautious ahead of the retail inflation data scheduled to be announced today.The BSE Sensex declined 10 points to close at 60,105, while the Nifty50 fell 18 points to end tad below 17,900 mark and formed small bodied bearish candle on the daily charts.The broader markets also followed similar kind of trend with the Nifty Midcap 100 and Smallcap 100 indices falling 0.32 percent and 0.05 percent respectively, but Bank Nifty bucked the trend, rising half a percent to close above 42,200 level.Stocks that were in action and outperformed the broader markets included Max Financial Services which was the third biggest gainer in futures and options segment, rising 3.7 percent to Rs 799, the highest closing level since September 22, 2022 and formed long bullish candle on the daily charts with above average volumes, making higher high higher low for second straight session. The stock has seen a breakout of horizontal resistance trend line adjoining September 29, 2022 and January 10, 2023.Oil India shares rallied more than 4 percent to Rs 222.85, the highest closing level since June 30, 2022 and formed strong bullish candle on the daily charts with healthy volumes, making higher high higher low for fourth consecutive session. The stock has seen a decisive breakout of horizontal resistance trend line adjoining December 14, 2022 and January 2, 2023 and also broke small downward sloping resistance trend line adjoining December 15, 2022 and January 2, 2023.Hindustan Petroleum Corporation was also in focus, rising nearly 3 percent to Rs 256.5, the highest closing level since August 19, 2022 and formed long bullish candle on the daily charts with strong volumes, making higher high higher low formation. The stock has seen a decisive breakout of horizontal resistance trend line adjoining September 13 and December 12, 2022, and also there was a breakout of downward sloping resistance trend line adjoining August 18, 2022, January 6, and January 9, 2023.Here's what Jigar S Patel of Anand Rathi Shares & Stock Brokers recommends investors should do with these stocks when the market resumes trading today:Oil IndiaSince the last four months, the said counter has been making higher highs and higher lows structure. Recently it broke its previous swing high of Rs 218.60 along with the four-month-old trendline is maintained and currently is sustaining above it 200 DEMA (day exponential moving average) thus hinting upside in the counter.On the indicator front, daily DMI (directional movement index) is in bullish mode and also it broke its previous swing thus indicating bullishness in the counter. Also, daily MACD (moving average convergence divergence) has made bullish cross above zero line thus giving extra confirmation for upside in the said counter (refer to the chart).One can buy in small tranches around Rs 221-224 and another around Rs 216-218, with a target at around Rs 250 and stop-loss at Rs 205.Max Financial ServicesRecently MFSL has broken its historical resistance of Rs 740 and comfortably it is sustaining above 200 DEMA (refer to the chart). Additionally, one year old trendline is violated thus confirming its early reversal.On indicator front, daily MACD and DMI are in displaying bulllish structure thus confirming bullishness in coming sessions. One can buy around Rs 790-800 levels with a target of Rs 900 and stop-loss at Rs 750.Hindustan Petroleum CorporationSince the last three months, the said counter has been making higher highs and higher lows structure. Recently it broke its previous swing high of Rs 253 along with the 14-month-old trendline is violated and currently is sustaining above it 200 DEMA thus hinting upside in the counter.On the indicator front, daily DMI is in bullish mode and also it broke its previous swing thus indicating bullishness in the counter. Also, daily MACD has made bullish cross above zero line thus giving extra confirmation for upside in the said counter (refer to the chart).One can buy in small tranches around Rs 257-259 and another around Rs 250-252. Target is expected at around Rs 285 and stop-loss would be Rs 245.",Max Financial Services Ltd.
"  January 12, 2023 / 02:57 PM IST  ",Paytm suffers steep 9% decline after Alibaba affiliate's likely sale of 2 crore shares,"Shares of Paytm plunged 8.8 percent on Thursday after parent One97 Communications Ltd recorded a series of block deals in which around 19.20 million shares, or 3 percent stake, of the company changed hands.Paytm suffered its steepest fall since November 22 to Rs 528 a share on Thursday. At 1.40pm, the stock was trading 549 on the BSE, down 5 percent from its previous close.The stock had traded in the green in 12 out of last 14 sessions since December 26 and gained 15 percent in this period.CNBC-TV18 on Thursday reported that Ant Financial, an affiliate of Alibaba Group, is the likely seller in the Paytm block deal. Ant Financial, as of September 2022, held 164.42 million shares or 24.88 percent stake in the company.According to Goldman Sachs calculations, Antfin Netherlands Holding had acquired shares between 2015 and 2019 at an average cost of Rs 300 a share. Meanwhile, had invested in Paytm in 2015 at an average cost of acquisition of Rs 330. It had a 6.26 percent stake as of September-end.On January 9, Paytm reported to exchanges that it disbursed 3.7 million loans worth Rs 3,665 crore in December, up 330 percent on-year. For the December quarter, its total disbursements jumped 357 percent to Rs 9,958 crore. Monthly transacting users jumped 32 percent to 85 million in December from 65 million a year ago. Gross merchandise value processed through the platform saw a 38 percent growth year-on-year in December to Rs 3.64 lakh crore.The digital payments company also added one million payment devices during October-December and the number of merchants paying subscription for payment devices touched 5.8 million as of December 2022.The company's consumer engagement was at its highest on Paytm Super App with average monthly transacting users at 85 million for the quarter ended December 2022, up 32 percent on a yearly basis.Paytm board in December approved buyback of shares worth Rs 850 crore ($103 million) through the open market route. The number of shares bought back will be 10.5 million at the maximum buyback price of Rs 810, representing 1.6 percent of the paid-up share capital. Paytm has $1.1 billion in cash as of September 2022 and $127 million outlay of cash for buyback.Also Read: Paytm buyback: The good, the bad, and the ugly",One 97 Communications Ltd.
"  January 12, 2023 / 01:23 PM IST  ",Adulteration concerns: US FDA warning letter to Sun Pharma questions manufacturing practices at Halol facility  ,"The US Food and Drug Administration (FDA) has slammed Sun Pharma, the country’s largest generic drug maker, for manufacturing violations such as failure to investigate discrepancies in batches of products, not cleaning equipment used in drug manufacturing and failing to prevent contamination at its Halol facility in Gujarat.In a warning letter, the FDA has highlighted a series of lapses at Sun Pharma’s Gujarat plant, which has been put on an import alert list by the US drug regulator.In the letter dated December 15, the FDA told Dilip Shanghvi, Managing Director, Sun Pharma, that it had observed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the Halol facility. “Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated,” the warning letter said.Also read | FDA's warning letter points to cGMP violations at Halol facility: Sun PharmaThe FDA inspected Sun Pharma’s Halol plant from April 26 to May 9, 2022.The company gave a detailed response to the US regulator on May 31 in response to Form 483. However, the FDA was not convinced and placed the Halol facility on import alert on December 7. In its letter, the US FDA pointed out that Sun Pharma failed to thoroughly investigate discrepancies in batches of products at the Halol facility.‘Putting patients at risk’The regulator said that in November 2021, despite experiencing significant media fill failure, resulting in serious flaws and risks, Sun Pharma failed to perform a timely risk assessment to evaluate if the quality and sterility of its distributed drug products were affected by these deficiencies.“You waited over five months to initiate a recall of the affected batches. The failure to proactively identify deficiencies and implement timely and sustainable corrective actions and preventive actions (CAPA) is unacceptable because it puts patients at risk,” the warning letter said.Also read | Sun Pharma clarifies on US FDA import alert on Halol plantThe FDA has further pointed out that Sun Pharma did not follow appropriate procedures to prevent contamination at the Halol facility. “Operators’ bodies and hands were in immediate proximity to the sterile active pharmaceutical ingredient (API) during dispensing, compounding, and syringe-loading in the filling station,” the letter said.The warning letter also said that the pharma giant had failed to establish an adequate system to monitor environmental conditions. “Vigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment,” it said.According to the warning letter, Sun Pharma had acknowledged the inadequacies of the environmental and personnel monitoring programme, stating that the drug products impacted by the observation are being recalled, and that the specific filling line involved in the observation was no longer in use. “You fail to adequately explain how your quality and operations management will ensure appropriate cleanroom design, control, aseptic practices, and cleanroom behaviour during production,” the letter said.Failure to investigate discrepanciesThe US FDA’s warning letter said that Sun Pharma had failed to use suitable equipment in manufacturing drug products.“It is your responsibility to ensure that only appropriately designed and maintained equipment are used in the manufacture of your drug products,” the drug regulator said. It further stated: “Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.”Sun Pharma has been asked to provide a comprehensive, independent assessment of its overall system for investigation of discrepancies and to provide an action plan detailing how it will fix this system.Drug contamination concernsThe warning letter from the US FDA also points out that Sun Pharma failed to sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the purity of a drug. The company has been asked to provide a comprehensive, independent retrospective assessment of cleaning effectiveness to evaluate the scope of cross-contamination hazards.Also read | FDA's warning letter points to cGMP violations at Halol facility: Sun PharmaSun Pharma has been told that basis the findings at the Halol facility, the firm does not have an effective quality system in accordance with CGMP.Company told to take corrective action immediatelyThe company has been asked to immediately carry out a comprehensive assessment of its global manufacturing operations to ensure that its systems, processes, and manufactured products conform to FDA requirements.“Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to assist your firm in meeting CGMP requirements,” the FDA said.The regulator, however, says that engaging a consultant does not relieve the firm of its obligation to comply with CGMP. “Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance,” the FDA said.",Sun Pharmaceutical Industries Ltd.
"  January 12, 2023 / 02:43 PM IST  ",A portfolio of 19 stocks to stick with for a rewarding 2023,"                        The year 2022 was difficult for the Indian stock market. Nevertheless, amid volatility and uncertainty, the market did throw up several winners. While the outlook for 2023 is clouded, with forecasts ranging from extreme optimism to pessimism, we believe a well-researched portfolio can still produce gainers. Here’s a 19-stock portfolio that can help navigate an uncertain year. Wishing all our readers a very Happy New Year and a rewarding year of investing with MC Pro.

The following are the 19...
                    ",Syngene International Ltd.
